Current approved options for treating patients with multiple sclerosis
- 28 December 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 63 (12_suppl_6), S8-S14
- https://doi.org/10.1212/wnl.63.12_suppl_6.s8
Abstract
Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immunosuppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS. Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.Keywords
This publication has 47 references indexed in Scilit:
- Current Disease-Modifying Therapies in Multiple SclerosisSeminars in Neurology, 2003
- Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up studyBrain, 2003
- Approved and Future Pharmacotherapy for Multiple SclerosisThe Neurologist, 2002
- A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapyMultiple Sclerosis Journal, 2001
- P81 – P162Neuroimmunomodulation, 1999
- Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Rating neurologic impairment in multiple sclerosisNeurology, 1983